<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01801644</url>
  </required_header>
  <id_info>
    <org_study_id>Bladder Cancer-001</org_study_id>
    <secondary_id>Bladder Cancer-001</secondary_id>
    <nct_id>NCT01801644</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer</brief_title>
  <official_title>Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barmherzige Brüder Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barmherzige Brüder Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of neoadjuvant gemcitabine and cisplatin (gem/cis) in
      locally advanced bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with locally advanced transitional cell bladder cancer receive 3 cycles of
      neoadjuvant gemcitabine/cisplatin before radical cystectomy.

      Patients with histologically confirmed clinical stage T2-T4a, N0-2 bladder cancer are going
      to be included. After CT scan of the thorax and abdomen plus MRI of the pelvis patient
      receive chemotherapy.

      Pathologic response rate will be assessed after surgery by the institutional pathologic
      review. Safety is going to be assessed according to the National Cancer Institute Common
      Toxicity Criteria (CTC,version 3.0).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic response rate</measure>
    <time_frame>at time of surgery</time_frame>
    <description>evaluation of the pathologic response rate after 3 cycles of neoadjuvant gemcitabine/cisplatin at time of radical cystectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety, number of participants with adverse events and grade of adverse events</measure>
    <time_frame>adverse events will be evaluated after every 6 months</time_frame>
    <description>to assess the safety of neoadjuvant gemcitabine/cisplatin in bladder cancer</description>
  </secondary_outcome>
  <other_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>up to 5 years after including the last patient</time_frame>
    <description>pfs will be assessed avery 3 months in the first year after radical cystectomy, every 6 months in the second year, and yearly from the 3rd year up to a minimum follow up of 5 years</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>gemcitabine plus cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemcitabine plus cisplatin: 3 cycles of gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion and cisplatin 70 mg/m2 on day 1 as an 2 hour infusion will be applied</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine plus cisplatin</intervention_name>
    <description>gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion</description>
    <arm_group_label>gemcitabine plus cisplatin</arm_group_label>
    <other_name>gemzar (gemcitabine) plus cisplatin (= cisplatin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age

          -  histologically confirmed stage T2, T3 or T4a urothelial bladder cancer with N0-N2

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  bone marrow reserve (neutrophil count &gt;1500 cells per μL,platelet count &gt;100 000 per
             μL) count

          -  hepatic function (serum bilirubin &lt;2,5 times the upper limit of normal, serum
             aminotransferase ≤2,5 times the upper limit of normal).

          -  renal function with a creatinine clearance &gt;60ml/min

        Exclusion Criteria:

          -  metastatic disease

          -  serious or uncontrolled concurrent medical illness

          -  pregnancy

          -  history of other malignancies (with the exception of excised cervical or basal skin or
             squamous-cell carcinoma)

          -  non-transitional cell bladder cancer

          -  creatinine clearance &lt;60ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Meran, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barmherzige Brüder Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barmherzige Brüder Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Nov 1;113(9):2471-7. doi: 10.1002/cncr.23848.</citation>
    <PMID>18823036</PMID>
  </reference>
  <results_reference>
    <citation>Tolerability of neoadjuvant chemotherapy with gemcitabine plus cisplatin in elderly (older than age 65) patients (pts) with muscle-invasive urothelial cancer. D. Niedersuess-Beke, B. Gruenberger, T. Puntus, W. Bauer, M. Lamche, P. Schramek, J. G. Meran; Barmherzige Brueder Hospital, Vienna, Austria; Goettlicher Heiland Hospital, Vienna, Austria ´ J Clin Oncol 29: 2011 (suppl 7; abstr 296)</citation>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barmherzige Brüder Vienna</investigator_affiliation>
    <investigator_full_name>Johannes Meran</investigator_full_name>
    <investigator_title>Prof. Dr.Johannes Meran</investigator_title>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>gem/cis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

